Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

A University of Alberta research team has taken the first step toward proving its innovative gene therapy can successfully ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...